Date: Saturday, June 11, 2016
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Halls C&D
Introduction: Liver transplantation (LT) is one of the best treatment for small hepatocellular carcinoma (HCC) in patients with liver cirrhosis. However, many patients do not have available donor. For that reason, many patients received the bridging therapy such as TACE, RFA, and surgical resection during the waiting LT. Furthermore, some patients need the down staging therapy for LT. The aim of this study is to evaluate the predictable values of recurrent HCC in patients received other treatment modality before LT.
Methods: The 261 recipients with HCC who underwent liver transplantation between January 2007 and December 2014 in Severance hospital were retrospectively reviewed. Among 261 patients, 189 patients received the other treatment such as TACE, RFA, chemotherapy, and surgical resection before LT.
The results: The mean age of the HCC recurrence group was younger than non-recurrence group (51.2 ± 6.1 vs 54.6 ± 6.9, p<0.006). There was no significant difference of the etiology of HCC between the groups. The patients above Milan criteria showed a higher tumor recurrence rate than those within Milan criteria in both diagnosis and transplantation. In univariate analysis, Milan criteria at first diagnosis, Milan criteria at liver transplantation, AFP≥200 ng/mL at first diagnosis, AFP≥200 ng/mL at liver transplantation, PIVKA≥100 mAU/mL at liver transplantation affected HCC recurrence. In multivariate analysis, Milan criteria at liver transplantation and PIVKA≥100 ng/mL at liver transplantation affected HCC recurrence. (Odds ratio 3.632 and 5.245, respectively)
including brackets, where you would like your figure to appear .
Conclusion: PIVKA ≥100 ng/mL and Milan criteria at transplantation are predictable value of post-transplant HCC recurrence in patients received down staging therapy or bridging therapy.
CITATION INFORMATION: Song S, Lee J, Kwon S.-K, Lee J, Lee J, Han D, Choi G, Kim M, Choi J, Kim S, Joo D. Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy? Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Song S, Lee J, Kwon S-K, Lee J, Lee J, Han D, Choi G, Kim M, Choi J, Kim S, Joo D. Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy? [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/which-is-the-predictable-values-of-post-transplant-hepatocellular-carcinoma-recurrence-in-patients-received-down-staging-therapy-or-bridging-therapy/. Accessed May 25, 2020.
« Back to 2016 American Transplant Congress